Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness

Sleep Medicine and Research Center, St. Luke's Hospital, 232 S. Woods Mill Road, Chesterfield, MO 63017, United States.
Sleep Medicine (Impact Factor: 3.15). 11/2009; 11(1):23-30. DOI: 10.1016/j.sleep.2009.07.012
Source: PubMed


Two doses of EVT 201, a partial positive allosteric modulator of the GABA(A) system, were evaluated in elderly primary insomnia patients with daytime sleepiness.
Participants were 149 elderly patients with DSM-IV primary insomnia including evidence of daytime sleepiness (53 males, 96 females; mean age 71.3yrs, range 65-86yrs). A randomized, multicentre, double-blind, placebo-controlled, parallel-group design was used to assess the hypnotic efficacy of EVT 201 1.5 and 2.5mg during seven consecutive nights. Polysomnography (PSG) was performed on nights 1, 6 and 7 of treatment. Daytime assessments on Day 8 included the multiple sleep latency test (MSLT), Rey Auditory Verbal Learning Test (RAVLT), Psychomotor Vigilance Task (PVT) and the Karolinska Sleepiness Scale (KSS). The primary endpoint was total sleep time (TST) and the key secondary endpoint was mean MSLT latency.
Compared to placebo, EVT 201 1.5 and 2.5mg increased TST (30.9, 56.4min, respectively; p=0.0001, p<0.0001); reduced wake after sleep onset (WASO; -15.2, -36.1min, respectively; p=0.014, p<0.0001); reduced latency to persistent sleep (LPS; -15.9, -19.9min, respectively; p=0.009, p=0.001). The 2.5mg dose also reduced WASO in hours 5-8 (-16.3min, p=0.001). Both doses also improved subjective sleep quality and usual subjective efficacy measures. A significantly longer mean MSLT latency was observed on Day 8 with both doses, compared to placebo (2min increase; p=0.03, both doses). The PVT, RAVLT, and POMS did not differ among treatment groups. No serious or unexpected treatment emergent adverse events were noted.
EVT 201 improved PSG measures of sleep onset and sleep maintenance and significantly reduced daytime physiological sleep tendency. These findings suggest that treatment of primary insomnia in older patients has the potential to improve daytime sleepiness as well as sleep.

1 Follower
7 Reads

  • Sleep Medicine 11/2009; 11(1):7-8. DOI:10.1016/j.sleep.2009.08.002 · 3.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is little doubt regarding the therapeutic possibilities of modulation of GABA A receptor function as exemplified by the clinical utility of benzodiaze-pines for half a century. The emerging understanding of the role of different GABA A receptor subtypes in mediating different physiological functions and pathological processes continues to offer opportunities for novel therapeutics. However, the challenge remains in turning the increased understanding of molecu-lar pharmacology of GABA A receptors into clinically efficacious drugs. Probably the most active area of research has been the search for a non-sedating anxiolytic that acts via the benzodiazepine binding site. Unfortunately, the clinical develop-ment of a number of drugs with promising pre-clinical profiles, such as ocinaplon, SL65.1498, pagoclone, MRK-409, TPA023 and TPA023B has halted for a variety of reasons. Therefore, the underlying hypothesis that sub-type-selective compounds are non-sedating anxiolytics in man remains to be adequately tested. As regards hypnotics, the benzodiazepine site compounds adipiplon and indiplon, as well as the GABA A a4bd-preferring agonist gaboxadol, are no longer in clinical develop-ment, leaving EVT-201, which has demonstrated efficacy in Phase II studies in primary insomnia, as the single, novel GABA A -mediated hypnotic currently under evaluation. Benzodiazepines remain the first-line treatment for status epilepticus, an indication for which, therefore, there would appear little need for GABA A subtype-selective compounds. With respect to epilepsy, modulation of GABA A receptor function via the neurosteroid recognition site is the mechanism of action of ganaxolone, which is currently being evaluated in Phase III studies in adult partial seizures and children with infantile seizures. The continually evolving understand-ing of the structure and function of not only the GABA A receptor but also the variety of diverse binding sites that it harbours should continue to provide the molecular basis for designing strategies to selectively modulate the function of, # Springer Basel AG 2010 25 distinct subtypes of the GABA A receptor and thereby provide novel therapies for the treatment of anxiety, sleep disorders, and possibly also epilepsy.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of primary insomnia may be complex and clinically challenging. A comprehensive multidimensional evaluation with a thorough history and physical examination coupled with appropriate testing/imaging will facilitate development of a working diagnosis. Optimal treatment strategies of challenging cases typically involve interdisciplinary team approaches (including a sleep medicine specialist) providing multimodal approaches to treatment, including nonpharmacologic and pharmacologic strategies. A stepped care approach to treatment may serve as a useful guide for health care providers unfamiliar with sleep disturbance issues. Treatment plans based on sound medical judgment, clinical insight, and a thorough and global understanding of particular patient's comorbid conditions may lead to optimal patient-specific/patient-focused/patient centered personalized care.
    American journal of therapeutics 02/2011; 18(3):227-40. DOI:10.1097/MJT.0b013e3182012fb4 · 1.13 Impact Factor
Show more